Hormone Replacement Therapy Side Effects: What May Settle, What Needs Review, and What Requires Urgent Care

Start with the severity question, not a universal safety label

Hormone replacement therapy side effects cannot be judged with a single safe-or-unsafe label. The useful first question is how serious a symptom may be, how long it has lasted, and whether the treatment and your health history change its meaning.

Menopausal hormone therapy and testosterone therapy are different treatment paths. Menopausal therapy may involve estrogen alone or estrogen with a progestogen, while testosterone replacement therapy is used for men with documented low testosterone caused by hypogonadism. Their potential effects, evidence, and monitoring questions should not be blended together.

A four-part check can keep the discussion practical:

• Potentially manageable effects: symptoms that may ease as your body adjusts and that a clinician may address through a treatment adjustment.
• Clinician-review concerns: symptoms that are severe, persistent, unusual, or troublesome enough to need an assessment.
• Urgent warning signs: symptoms that may indicate a serious problem and require immediate medical help.
• Longer-term uncertainties: risks that depend on age, timing, formulation, route, dose, duration, medical history, and treatment purpose.

For healthy women younger than 60 or within 10 years of menopause, one review describes hormone-therapy risks as low and says benefits are likely to outweigh risks for bothersome vasomotor symptoms. That conclusion does not apply automatically to every person or regimen. In the combined estrogen–progestin arm of the Women’s Health Initiative, coronary heart disease risk had a hazard ratio of approximately 1.29 in the early years and stroke risk had a hazard ratio of approximately 1.31, particularly among older women or those starting later after menopause.

A large study also found that hormone replacement therapy exposure in the previous 90 days was associated with a 43% higher venous thromboembolism risk than no use in the previous year. The result describes a study association, not your personal probability. Use the severity check before deciding what a symptom means.

Your age, reason for treatment, route, dose, formulation, and health history all matter. Menopausal hormone therapy is not indicated for cardiovascular prevention, and a treatment discussion should connect possible benefits with the risks that fit your circumstances rather than relying on a general headline.

Recognize effects that may settle after treatment begins

Common menopausal hormone therapy side effects can include breast tenderness, bloating, headaches, nausea, mood changes, stomach upset, fluid retention, vaginal bleeding, and changes in appetite, weight, or sleep. Most side effects are mild and often settle within a few weeks, while several symptoms may take longer to improve.

You can use the pattern and duration as a starting point, not as a diagnosis:

• Breast tenderness, bloating, headaches, nausea, and mood changes often ease within a few weeks to 3 months.
• Irregular spotting is common at first and usually settles within 6 months.
• With continuous combined HRT, irregular bleeding or spotting is common during the first 4 to 6 months.
• Headache, stomach upset, mood changes, fluid retention, vaginal bleeding, and breast tenderness should be discussed if they are severe or do not go away.

The timing of spotting matters, but timing alone does not prove that bleeding is harmless. A new symptom can have another cause, and the treatment type, regimen, age, and medical history affect how a clinician interprets it.

Age is one part of the assessment, not an automatic answer. If you are 65 or older, or if symptoms are changing after treatment begins, ask a qualified clinician to reassess the treatment rather than judging it from a general side-effect list.

Separate a manageable effect from one that needs review

Persistent or troublesome hormone therapy symptoms deserve a clinician review even when they began soon after treatment. A clinician may manage common side effects by changing the dose, preparation, regimen, or route, but you should not make those changes on your own.

A useful distinction is whether the symptom is mild and improving, or whether it is severe, persistent, unexplained, or affecting daily life. Bring the symptom, its start date, its pattern, and any treatment change to the appointment. That information helps separate an expected adjustment from a problem that needs a different explanation.

Early spotting can occur with continuous combined HRT, but persistent or concerning irregular bleeding may require endometrial biopsy and gynecologic referral, especially when symptoms do not respond to treatment adjustments.

Contact the prescribing clinician about bleeding that is heavy, persistent, recurrent after an established pattern, or otherwise concerning. Seek immediate help for unusual bleeding accompanied by severe symptoms. The practical boundary is simple: expected timing may provide context, but it does not replace assessment when bleeding continues or changes.

Understand why the same therapy can carry different risks

Hormone therapy route changes how widely hormones affect your body. Systemic therapy uses pills, patches, sprays, gels, or a vaginal ring and affects the body more widely. Low-dose vaginal therapy has very little absorption into the bloodstream and far lower risks than systemic therapy, although your own health history still matters.

Your HRT risks depend on your age, treatment type and dose, personal medical history, and risks involving cancer, heart disease, stroke, blood clots, liver disease, and osteoporosis. The reason for treatment also matters: symptom relief, local genitourinary symptoms, and another treatment purpose may lead to different options and risk discussions.

Starting menopause hormone therapy at age 60 or older, or more than 10 years after menopause, increases the risk of serious complications. Starting before age 60 or within 10 years of menopause may have a more favorable benefit–risk balance. These are population-level findings, not an eligibility decision for you.

Route can also change clot findings. In one study, oral HRT was associated with higher venous thromboembolism risk, with an adjusted odds ratio of 1.58 and a 95% confidence interval of 1.52 to 1.64, while transdermal HRT was not associated with VTE risk, with an adjusted odds ratio of 0.93 and a 95% confidence interval of 0.87 to 1.01. In that same study, oral HRT was associated with a 70% higher VTE risk than transdermal HRT.

The study result does not mean that a patch, gel, or other route eliminates risk. It means route belongs in the clinical conversation. Menopausal hormone therapy is not indicated for cardiovascular prevention, and the FDA removed most of the boxed warning on HRT labels in 2025, as reported in the cited patient information. Label changes do not turn individualized risk assessment into a universal recommendation.

Read cardiovascular and clot evidence in context

Cardiovascular hormone-therapy findings are not uniform because studies have examined different ages, regimens, routes, and outcomes. One randomized analysis found that HRT did not significantly affect cardiovascular risk among women aged 50 to 59 with vasomotor symptoms, while cardiovascular risk increased among women aged 70 years and older with vasomotor symptoms.

A Swedish nationwide emulated target trial reached a different conclusion for a different outcome and treatment comparison. The study included 919,614 women aged 50 to 58 years. Oral estrogen–progestin therapy was associated with increased ischemic-heart-disease risk, with a hazard ratio of 1.21 and a 95% confidence interval of 1.00 to 1.46, while transdermal regimens showed no significant increase in cardiovascular risk. The same study linked oral combined continuous therapy or tibolone with higher cardiovascular risk within the first 2 years, while transdermal regimens were not linked to higher overall cardiovascular risk.

These findings can coexist because overall cardiovascular disease and ischemic heart disease are not identical outcomes, and a randomized age-stratified analysis is not the same as a nationwide emulated trial. The treatment regimen and route also differ. The practical conclusion is not that one route is universally safe or unsafe; it is that age, timing, formulation, route, and existing cardiovascular risk must be considered together.

Clot evidence also needs an absolute-risk frame. One large study associated HRT exposure with a 43% higher VTE risk than no HRT exposure in the previous year, with oral HRT showing an adjusted odds ratio of 1.58 and transdermal HRT showing an adjusted odds ratio of 0.93. The cited Women’s Health Initiative data reported a 1%–2% absolute incidence of VTE over 5–7 years among people taking oral hormone therapy.

The 1%–2% figure measures absolute VTE incidence in that cited population and time period; it is not a prediction for you. Ask which risk estimate fits your age, medical history, treatment type, route, and duration.

Put longer-term risks beside potential benefits

Longer-term hormone therapy findings depend on the regimen and the population studied. In one study of postmenopausal women with an intact uterus, combined continuous HRT probably increased breast cancer risk, with a relative risk of 1.27 and a 95% confidence interval of 1.03 to 1.56. The same treatment probably reduced clinical fractures, with a relative risk of 0.78 and a 95% confidence interval of 0.71 to 0.86, and may have increased VTE risk, with a relative risk of 2.03 and a 95% confidence interval of 1.55 to 6.64.

In one study of postmenopausal women who had undergone hysterectomy, estrogen-only HRT probably increased stroke risk, with a relative risk of 1.33 and a 95% confidence interval of 1.06 to 1.67. Estrogen-only HRT probably increased gallbladder disease requiring surgery, with a relative risk of 1.78 and a 95% confidence interval of 1.42 to 2.24, while probably reducing clinical fractures, with a relative risk of 0.73 and a 95% confidence interval of 0.65 to 0.80.

Longer use of combination HRT was associated with higher breast cancer risk in 20-year follow-up, although absolute risk was low compared with placebo. Estrogen-only HRT lowered breast cancer risk among women with prior hysterectomies in the studied age groups. These results do not let you calculate your personal risk without knowing the treatment, duration, age, history, and comparison being used.

Potential benefit belongs in the same conversation as potential harm. When there are no contraindications, HRT may be a good option for vasomotor symptoms; the cited clinical guidance reports a 75% reduction in hot flashes for most patients. MHT is also described as the most effective treatment for vasomotor symptoms and as first-line treatment for genitourinary syndrome of menopause, especially low-dose local vaginal estrogen.

A separate meta-analysis assessed 26 randomized controlled trials involving 10,941 participants and examined mortality, cardiovascular outcomes, myocardial infarction, stroke, heart failure, atrial fibrillation, pulmonary embolism, and venous thrombosis. The number of trials and participants describes that analysis, not your expected outcome. Ask which benefit you are pursuing, which risk matters most for you, and whether a nonhormonal or local option could address the same symptom.

Use a separate safety lens for testosterone therapy

Testosterone replacement therapy requires its own evaluation and should not borrow conclusions from menopausal HRT. Testosterone replacement therapy is an option for men with low testosterone caused by male hypogonadism and uses manufactured testosterone to regulate hormone levels. The cited guidance recommends considering treatment for men with low testosterone and clinical symptoms of hypogonadism, particularly sexual dysfunction.

Before testosterone treatment starts, low morning testosterone should be documented on 2 occasions. That testing requirement helps distinguish a documented hormone disorder from nonspecific symptoms such as fatigue, low mood, decreased strength, or reduced vitality, which can have many causes.

Long-term testosterone safety remains uncertain, including possible cardiovascular harms. A qualified clinician should discuss the risks and benefits with you before treatment, especially if you have had a previous thromboembolic event or have other cardiovascular concerns.

A randomized testosterone trial reported similar rates of its primary cardiovascular end point in the testosterone and placebo groups. The hazard ratio was 0.96, with a 95% confidence interval of 0.78 to 1.17. The trial also observed a higher incidence of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group.

Atrial fibrillation occurred in 91 patients, or 3.5%, receiving testosterone, compared with 63 patients, or 2.4%, receiving placebo. Those findings do not establish that testosterone caused every event or predict what will happen to you, but they show why cardiovascular and clot questions belong in the evaluation.

Blood-count monitoring is another testosterone-specific concern. A preexisting hematocrit above 54% is an absolute contraindication to starting testosterone therapy. If hematocrit rises above 54% during treatment, a clinician should consider stopping treatment, lowering the dose, or changing to a lower-risk formulation. Regular monitoring can include testosterone measurements, a complete blood count for hematocrit, and PSA testing.

Prepare questions before starting or changing therapy

A hormone therapy consultation should answer a defined set of questions before you start or change treatment. Write down your symptoms, their timing, previous diagnoses, medicines, surgeries, family history, and what you want treatment to improve. Then ask:

1. What is the treatment purpose? Ask which symptom or documented condition the treatment is intended to address and what other explanations should be considered.
2. What personal risks change the decision? Before systemic HRT, clinicians screen for conditions such as breast cancer, prior VTE or stroke, coronary artery disease, active liver disease, uncontrolled hypertension, and unexplained vaginal bleeding. Mention prior cancer, blood clots, stroke, heart disease, high blood pressure, and other relevant conditions.
3. Which formulation and route fit the purpose? Ask why a clinician recommends oral, transdermal, local vaginal, or another formulation, and what route-specific risks apply.
4. What alternatives could address the same symptom? If HRT is not appropriate, ask which alternatives address your symptoms and what trade-offs they carry.

Follow-up questions should be just as specific:

• Which symptoms, vital signs, laboratory values, or other findings will be monitored?
• When will the treatment be reassessed, and what would lead to an adjustment?
• For testosterone therapy, should testing include a complete blood count, PSA test, and digital rectal examination before treatment, with reevaluation 3 to 6 months after treatment begins?
• How long might treatment continue, and what would make the balance change over time?

At True You Health and Wellness, our process includes comprehensive labs and a thorough conversation; we use hormone therapy only when the data and symptoms support it. We review duration regularly with you based on your goals, symptoms, and health over time. Our hormone therapy follow-ups are often virtual so we can track how you feel, retest when needed, and adjust treatment.

Know what to do when a warning sign appears

Emergency warning signs during or after hormone therapy include crushing chest pain, sudden shortness of breath, coughing up blood, a swollen painful leg, or signs of a stroke. Sudden severe headache, sudden severe vomiting, speech problems, faintness, sudden vision loss, or weakness or numbness in an arm or leg also require immediate medical attention.

If any of these symptoms occur:

• Seek emergency care rather than waiting for a routine appointment.
• Tell emergency personnel which hormone treatment you use, the formulation and route if known, and when you last used it.

Unusual vaginal bleeding, a painful or red leg, or other serious symptoms require immediate contact with a doctor even when the cause is uncertain. A symptom should be evaluated rather than labeled as a routine adjustment.

Do not start, stop, or change hormone doses on your own in response to a concerning symptom. When there is no new diagnosis that contraindicates continuing HRT, treatment may be stopped abruptly or gradually; tapering is commonly advised for returning vasomotor symptoms, but its comparative effectiveness is unknown. Discuss the plan with the responsible clinician.

Tell your doctor or dentist that you take HRT before surgery, including dental surgery. If testosterone treatment is followed by a new or changing bleeding pattern, discuss it with a doctor; an ultrasound or other testing may be requested.

Seek qualified evaluation for symptoms that do not fit the expected pattern

Testosterone therapy has additional monitoring boundaries. Patients should be reevaluated 3 to 6 months after starting testosterone therapy for treatment response and adverse effects, with repeat testosterone, complete blood count, digital rectal examination, and PSA testing.

A PSA increase greater than 1.4 ng per mL, or 1.4 mcg per L, over 12 months, or an abnormal digital rectal examination should prompt referral to a urologist. Testosterone therapy is contraindicated in men with untreated prostate cancer or breast cancer. Other concerns to monitor include polycythemia, peripheral edema, and cardiac or hepatic dysfunction.

Taking more testosterone will not make changes progress faster, but it could cause serious side effects or complications. Excess testosterone can cause mood symptoms or irritability, bloating, pelvic cramping, or a return of menstruation. Discuss these changes rather than trying to correct them by self-adjusting the dose.

Bring the treatment-specific question list to the next conversation

A treatment-specific question list can help you enter the next conversation prepared rather than alarmed. Bring the symptom pattern, treatment name and route, relevant health history, and the questions that matter most:

• Which effects may settle, and how long should you watch them?
• Which symptoms require a prompt call, and which require emergency care?
• How do your age, medical history, treatment purpose, formulation, route, and dose affect the balance?
• What monitoring will show whether the treatment remains appropriate?
• What alternatives are available if the risks outweigh the expected benefit?
• What should you do if bleeding, chest symptoms, neurologic symptoms, or other warning signs appear?

A qualified professional decides individual suitability after reviewing your symptoms, history, examination, treatment details, and relevant testing. If you are considering hormone therapy in or around Fredericksburg, True You Health and Wellness can begin that discussion through a process that uses comprehensive labs, a thorough conversation, and treatment only when the data and symptoms support it.

What should I ask about hormone replacement therapy side effects?

What are the long-term side effects of hormone replacement therapy?

Long-term effects depend on the hormone, formulation, route, dose, duration, age, treatment purpose, and health history. Evidence describes possible increases in risks such as blood clots, stroke, cardiovascular events, breast cancer with some combined menopausal regimens, or polycythemia with testosterone. Some treatments may also reduce symptoms or fractures. These findings are not a personal prediction, so review the expected benefit, alternatives, and follow-up plan with a qualified clinician.

Is hormone replacement therapy safe after age 65?

It may not be appropriate for everyone aged 65 or older because other options may be safer or work better. Age alone does not determine the decision, but starting later or more than 10 years after menopause can increase the risk of serious complications. A clinician should reassess the treatment purpose, medical history, formulation, route, dose, and alternatives rather than continuing or starting therapy based on age alone.

Does the form of HRT affect blood-clot risk?

Yes. In one study, oral HRT was associated with higher venous thromboembolism risk, while transdermal HRT was not associated with VTE risk; patches, gels, and sprays are also described as carrying lower clot and stroke risk than pills. This does not eliminate risk or make one route universally appropriate. Ask why a particular route fits your symptoms and health history.

What should I do if bleeding continues while taking HRT?

Contact the prescribing clinician about bleeding that is heavy, persistent, recurrent after an established pattern, or otherwise concerning. Early spotting can be common with some regimens, but persistent or concerning bleeding may require further evaluation, including gynecologic referral or an endometrial biopsy. Do not change or stop the dose on your own while waiting for advice unless emergency clinicians instruct you to do so.

Can I stop hormone replacement therapy suddenly?

When there is no new diagnosis that makes continuing unsafe, HRT may be stopped abruptly or gradually. Tapering is commonly advised to help limit returning vasomotor symptoms, but its comparative effectiveness is uncertain. Discuss the approach with the responsible clinician, and seek prompt medical guidance instead of stopping independently when serious symptoms or a new contraindication occurs.